38.46
1.07 (2.86%)
| Previous Close | 37.39 |
| Open | 37.50 |
| Volume | 648,870 |
| Avg. Volume (3M) | 1,128,593 |
| Market Cap | 2,139,758,208 |
| Price / Sales | 6.84 |
| Price / Book | 5.02 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | -36.20% |
| Operating Margin (TTM) | -39.67% |
| Diluted EPS (TTM) | -1.69 |
| Quarterly Revenue Growth (YOY) | 55.30% |
| Total Debt/Equity (MRQ) | 21.02% |
| Current Ratio (MRQ) | 8.95 |
| Operating Cash Flow (TTM) | -83.91 M |
| Levered Free Cash Flow (TTM) | -58.77 M |
| Return on Assets (TTM) | -13.36% |
| Return on Equity (TTM) | -27.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | PROCEPT BioRobotics Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 1.00 |
|
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 4.22% |
| % Held by Institutions | 93.06% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (Oppenheimer, 56.01%) | Buy |
| Median | 56.50 (46.91%) | |
| Low | 50.00 (Truist Securities, 30.01%) | Buy |
| Average | 55.75 (44.96%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 38.13 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 15 Oct 2025 | 50.00 (30.01%) | Buy | 33.76 |
| Oppenheimer | 02 Sep 2025 | 60.00 (56.01%) | Buy | 39.57 |
| Piper Sandler | 07 Aug 2025 | 55.00 (43.01%) | Buy | 39.59 |
| Wells Fargo | 07 Aug 2025 | 58.00 (50.81%) | Buy | 39.59 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 Oct 2025 | Announcement | PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025 |
| 06 Aug 2025 | Announcement | PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |